増加した心臓のアドレネルジック駆動は,ヒトの心不全における一般化された交感性活性化に先行する
B Rundqvist1, M Elam, Y Bergmann-Sverrisdottir
1Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden. bengtr@wlab.wall.gu.se
Circulation
|January 7, 1997
まとめ
早期の閉塞性心不全 (CHF) は,心臓のノルエピネフリン (NE) の溢出が増加し,心臓のアドレネルギー駆動が増加していることを示す. これは,進行したCHFで見られる広範囲にわたる交感神経系の活性化前に起こります.
科学分野:
- 心臓病学 心臓病学
- 神経科学は神経科学である.
- 生理学 生理学とは
背景:
- 以前の研究では,重度の閉塞性心不全 (CHF) の心臓および腎臓のノルアピネフリン (NE) の溢出が増加することを示唆しています.
- 初期段階のCHFにおける地域共感神経系の活動に関するデータは限られている.
- この研究では,心臓,腎臓,骨格筋の共感機能が,CHFの重症度を超えて調査されています.
研究 の 目的:
- 軽度から中度,重度の心筋梗塞の地域共感神経系の活動を評価する.
- CHFの患者と健康な対照群の共感性プロフィールを比較する.
- 初期のCHFで心臓のアドレネルジックドライブが変化しているかどうかを判断する.
主な方法:
- [3H]NE注入による同位体希釈を用いて,心臓と腎臓からのNE溢出を評価した.
- 骨格筋の血管床 (MSA) への交感神経の流れを,神経内記録で測定した.
- 健康な被験者,軽度から中等度のCHF,重度のCHFグループにおけるNEの転移とMSAを比較した.
主要な成果:
- コントロールと比較して,軽度から中等度の (3倍) と重度の (4倍) CHFの両方で,心臓NEの溢出が著しく上昇しました.
- MSAと併せて全身および腎臓のNE溢出は,軽度から中等度のCHFでは異なっていないが,重度のCHFでは上昇した.
- [3H]NEの断片抽出は,心臓経由で,両CHF群で約40%減少した.
結論:
- 軽度から中等度のCHFは,心臓のアドレネルギー駆動の選択的な増加を示します.
- この増加した心交感活性が,進行性CHFで観察される一般化された交感活性化に先行する.
- 発見は,CHFの進行における交感神経系の関与の明確なパターンを示唆しています.
関連する概念動画
Sympathetic Activation
The sympathetic division can influence tissues and organs by releasing norepinephrine at peripheral synapses and distributing epinephrine and norepinephrine through the bloodstream. In times of crisis or stress, sympathetic activation occurs, which is regulated by sympathetic centers in the hypothalamus. As a result, sympathetic activation prepares the body for physical exertion, rapid ATP production, and heightened alertness, allowing individuals to respond effectively to challenging or...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


